US MedTech: NY Valves 2026: Day One Brings a Smorgasbord of Structural Heart Data

Research evidence excerpt

US MedTech: NY Valves 2026: Day One Brings a Smorgasbord of Structural Heart Data

Flash |

24 Jun 2026 15:37:07 ET │ 11 pages

US MedTech

NY Valves 2026: Day One Brings a Smorgasbord of Structural Heart Data

CITI’S TAKE

We attended day one of NY Valves 2026 (previously TVT), where

incremental TAVR data continues to build clinical support for

transcatheter technology. Edward Lifesciences’ PARTNER 3 7-Year

durability data (link) took center stage, with TAVR and surgery

demonstrating “comparable and sustained valve durability” given low and Joanne WuenschAC

similar rates of structural valve deterioration (SVD), all-cause +1-212-816-9606

bioprosthetic valve dysfunction (BVD), and reintervention (6% TAVR joanne.wuensch@citi.com

versus 5.5% Surgery) through 7 years. Medtronic’s Evolut also shared the

Anthony Occhiogrosso

spotlight, with the VA-CART program, 8-Year durability and

+1-212-816-7579

reintervention data, and 6-Year outcomes from the Evolut low-risk anthony.occhiogrosso@citi.com

bicuspid study demonstrating: 1) higher intervention in younger patients;

and 2) the need to build long-term data across patient risk levels, with the Jane-Marie Lai

next several years’ follow-up data being “critical” to long-term TAVR +1-212-816-3628

utilization. From the podium, physicians called the data “reassuring”, and janemarie.lai@citi.com

we are incrementally more positive on the TAVR landscape. We rate EW Nikhil Guddeti

(Top Pick) and MDT Buy. +1-212-816-2606

nikhiltej.guddeti@citi.com

Other takeaways. Amongst the smorgasbord of real-world and RCT data presented

today, certain results were not as “clean”, with data from real-world trials showing

higher mortality risks and reintervention rates versus RCT trials, somewhat

contradicting established conclusions.